Earnings ·
Stryker reports Q3 net sales of $6.5B, raises share buyback authorization by $3.0B
SYKStryker Corp
Stryker reported third-quarter 2026 operating results with net sales increasing 7.7% to $6.5 billion and organic net sales rising 7.7%. Reported diluted EPS decreased 11.7% to $1.96, while adjusted diluted EPS increased 10.3% to $3.52. The company repurchased $1.0 billion of common stock during the quarter and announced that its Board of Directors approved an additional $3.0 billion to its existing share repurchase program. Stryker updated its full-year 2026 guidance, expecting organic net sales growth between 6.5% and 7.0% and adjusted diluted EPS in the range of $14.80 to $14.90. The company operates as a global leader in medical technologies, offering innovative products and services in MedSurg, Neurotechnology, and Orthopaedics.